How would you manage grade 3 treatment-emergent diabetes mellitus (HbA1c of 11.1, anti-GAD65) in a patient with ES-SCLC on atezolizumab maintenance?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?

Would you give consolidation durvalumab to a patient who underwent chemoradiation for his stage III NSCLC and is being started on antifibrotic therapy by pulmonology for his ILD?

Would you use consolidation immunotherapy after chemoradiation for patients with stage III NSCLC and EGFR amplification?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.